middle.news
Dimerix finds stronger biological case for DMX-200 in FSGS
9:27am on Friday 23rd of October, 2026 AEDT
•
Biotechnology
Read Story
Dimerix finds stronger biological case for DMX-200 in FSGS
9:27am on Friday 23rd of October, 2026 AEDT
Key Points
NEPTUNE study analysed 261 FSGS patients
Higher CCR2 activity was associated with declining kidney function
Elevated urinary MCP-1 was linked to a composite kidney endpoint
Findings align with Phase 2 biomarker data for DMX-200
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE